AbbVie would gain an experimental eczema drug by buying biotech: report
MarketWatch· Jaimy Lee· Jun 20, 2026 · 4:11 PM
AbbVie is reportedly trying to buy a biotech company that is developing a promising atopic dermatitis drug for $10.9 billion in cash, according to a Financial Times report.
This is a summary. Read the complete story at MarketWatch below.
Read full article at MarketWatchRelated Stories
marketsabout 3 hours ago
Investors worry the bull market is getting old. But history shows it can continue to age gracefully.
Contrary to a widespread current worry among some on Wall Street, bull markets do not die of old age,
MarketWatch
marketsabout 3 hours ago
Brazilian stocks are breaking out as investors look for opportunities beyond tech
Brazil’s presidential election is powering optimism in the country’s stock market — and capturing the attention of investors wary of having too much exposure to U.S. stocks.
MarketWatch
marketsabout 4 hours ago
Nvidia and AMD shares fall as new AI announcements fail to re-energize investors
The chip makers introduced hardware and software designs for future AI data centers, but the revenue potential is still far out, an analyst says.
MarketWatch